Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetic Macular Edema: early-phase trial registry
10 of 64 indexed Diabetic Macular Edema trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #215 of 28,707 conditions by registered trial count.
64 US clinical trials · 10 currently recruiting · #215 of 28,707 conditions by registered trial count
Diabetic Macular Edema: 64 US clinical trials tracked, 10 recruiting.
Diabetic Macular Edema is the subject of 64 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 18 are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 5 of these trials.
Enrollment posture brief
Registry condition diabetic-macular-edema
OPEN 10 | RECR 16% | LATE 18 | EARLY 38 | RANK #215 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Bacterial Infections (16% recruiting · 19 trials)
Diabetic Macular Edema lists 10 open slots (16% of 64 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetic Macular Edema on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetic Macular Edema is recruiting below its size-band peers.
10 of 64 indexed trials (15.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetic Macular Edema trials is spread across many organizations.
Hoffmann-La Roche accounts for 5 of 64 trials (7.8%). 47 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetic Macular Edema enrolment sits around 93 participants.
Median target enrolment is 93 among the 64 trials that report a genuine target (sentinel values excluded). 33 of those (51.6%) plan for fewer than 100 participants.
-
Diabetic Macular Edema research is mostly interventional.
58 interventional and 6 observational studies make up this index (90.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
64 total, page 2 of 2
Ocular Safety and Usability Study for FYB203 PFS
Formycon
NCT06708637
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
Southeast Retina Center, Georgia
NCT03340610
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
David M. Brown, M.D.
NCT01552408
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
EyePoint Pharmaceuticals
NCT06099184
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
Oxular Limited
NCT05512962
The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
South Coast Retina Center; Carson, McBeath, Boswell
NCT02448446
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
Novartis Pharmaceuticals
NCT04635800
Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Santen SAS
NCT00665106
Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema
Clearside Biomedical
NCT02949024
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
KalVista Pharmaceuticals
NCT02193113
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
ThromboGenics
NCT03666923
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
ThromboGenics
NCT03511898
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
Vitreo-Retinal Associates, Michigan
NCT03097068
Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study
Medical College of Wisconsin
NCT00846092
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 15 |
| Phase 3 | 11 |
| Phase 4 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetic Macular Edema records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetic Macular Edema trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetic Macular Edema page
64 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Diabetic Macular Edema trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Hoffmann-La Roche sponsors the most Diabetic Macular Edema trials on record, review their full trial history before evaluating a specific study. See Hoffmann-La Roche's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Macular Edema condition card totals 64 registered trials; most-linked intervention Faricimab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.